Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients.
Future Oncol
; 12(10): 1243-9, 2016 May.
Article
em En
| MEDLINE
| ID: mdl-26888425
ABSTRACT
AIM:
The ALK inhibitor, crizotinib, has demonstrated effectiveness in patients with non-small-cell lung cancer harboring ALK rearrangements. As few studies of the clinical characteristics of Chinese patients with ALK rearrangements have been reported, we conduct this study to gain more understanding in such area among Chinese patients. PATIENTS &METHODS:
We undertook a retrospective study of 288 non-small-cell lung cancer patients admitted to our institution over a period of 4.5 years.RESULTS:
Following testing, 14.9% of the patients (43/288) were found to be ALK fusion gene positive. Patient data including gender, age, smoking status, EGFR mutation status and medical imaging data were collected and analyzed.CONCLUSION:
The findings suggested that patients with ALK rearrangements are more likely to be young, have EGFR wild-type, and more likely to exhibit mucus secretion, solid tumor growth, lymph node metastasis and pleural metastasis.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptores Proteína Tirosina Quinases
/
Carcinoma Pulmonar de Células não Pequenas
/
Povo Asiático
/
Neoplasias Pulmonares
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article